Drug intelligence / Profile preview

IVS-4001

Development stage: Preclinical
Lead developer: Invectys
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**IVS-4001** is a monoclonal antibody (mAb) developed by Invectys for treating early-stage tumor development. It targets **HLA-G** (human leukocyte antigen G), a non-classical MHC class I molecule that acts as an immune checkpoint by inhibiting immune responses through interactions with inhibitory receptors like ILT2 (LILRB1) and ILT4 (LILRB2) on immune cells, thereby promoting tumor immune evasion. IVS-4001 features high affinity for novel HLA-G isoforms, aiming to block this immunosuppressive activity in neoplasms, particularly solid tumors.[1][3][9]

Targets

HLA-G (Human leukocyte antigen G)

Beyond the preview

Go deeper on IVS-4001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVS-4001.

Explore the full profile